Peyton M Kurtz, Jason VanLandingham, Michael Cormican, Kyle Gibson, Leslie Roebuck
{"title":"评价创伤患者右美托咪定致低血压的剂量和滴定方案的效果。","authors":"Peyton M Kurtz, Jason VanLandingham, Michael Cormican, Kyle Gibson, Leslie Roebuck","doi":"10.1097/JTN.0000000000000721","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dexmedetomidine is an α-2 receptor agonist commonly used as a continuous infusion for sedation and analgesia; however, dose-dependent hypotension may limit its utility. Despite its widespread use, there is no consensus on appropriate dosing and titration.</p><p><strong>Objective: </strong>The objective of this study was to determine whether a dexmedetomidine dosing and titration protocol is associated with decreased rates of hypotension in trauma patients.</p><p><strong>Methods: </strong>This pre-post intervention study took place at a Level II trauma center in the Southeastern United States from August 2021 to March 2022 and included patients admitted by the trauma service to either the surgical trauma intensive care unit or intermediate care unit and received dexmedetomidine for greater than or equal to 6 hours. Patients were excluded if they were hypotensive or on vasopressors at baseline. The primary outcome was incidence of hypotension. Secondary outcomes included dosing and titration practices, initiation of a vasopressor, incidence of bradycardia, and time to goal Richmond Agitation Sedation Scale (RASS) score.</p><p><strong>Results: </strong>Fifty-nine patients met inclusion criteria: 30 in the pre-intervention group and 29 in the post-intervention group. Protocol adherence in the post group was 34% with a median of one violation per patient. Rates of hypotension were similar between the groups (60% vs. 45%, p = .243) but significantly lower in the post group patients with zero protocol violations (60% vs. 20%, p = .029). The post group also had a significantly lower maximal dose (1.1 vs. 0.7 μg/kg/hr, p < .001). There were no significant differences in the initiation of a vasopressor, incidence of bradycardia, or time to goal RASS.</p><p><strong>Conclusion: </strong>Adherence to a dexmedetomidine dosing and titration protocol significantly decreased incidence of hypotension and maximal dexmedetomidine dose without increasing time to goal RASS score in critically ill trauma patients.</p>","PeriodicalId":0,"journal":{"name":"","volume":"30 3","pages":"158-163"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating the Effect of a Dosing and Titration Protocol on Dexmedetomidine-Induced Hypotension in Trauma Patients.\",\"authors\":\"Peyton M Kurtz, Jason VanLandingham, Michael Cormican, Kyle Gibson, Leslie Roebuck\",\"doi\":\"10.1097/JTN.0000000000000721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dexmedetomidine is an α-2 receptor agonist commonly used as a continuous infusion for sedation and analgesia; however, dose-dependent hypotension may limit its utility. Despite its widespread use, there is no consensus on appropriate dosing and titration.</p><p><strong>Objective: </strong>The objective of this study was to determine whether a dexmedetomidine dosing and titration protocol is associated with decreased rates of hypotension in trauma patients.</p><p><strong>Methods: </strong>This pre-post intervention study took place at a Level II trauma center in the Southeastern United States from August 2021 to March 2022 and included patients admitted by the trauma service to either the surgical trauma intensive care unit or intermediate care unit and received dexmedetomidine for greater than or equal to 6 hours. Patients were excluded if they were hypotensive or on vasopressors at baseline. The primary outcome was incidence of hypotension. Secondary outcomes included dosing and titration practices, initiation of a vasopressor, incidence of bradycardia, and time to goal Richmond Agitation Sedation Scale (RASS) score.</p><p><strong>Results: </strong>Fifty-nine patients met inclusion criteria: 30 in the pre-intervention group and 29 in the post-intervention group. Protocol adherence in the post group was 34% with a median of one violation per patient. Rates of hypotension were similar between the groups (60% vs. 45%, p = .243) but significantly lower in the post group patients with zero protocol violations (60% vs. 20%, p = .029). The post group also had a significantly lower maximal dose (1.1 vs. 0.7 μg/kg/hr, p < .001). There were no significant differences in the initiation of a vasopressor, incidence of bradycardia, or time to goal RASS.</p><p><strong>Conclusion: </strong>Adherence to a dexmedetomidine dosing and titration protocol significantly decreased incidence of hypotension and maximal dexmedetomidine dose without increasing time to goal RASS score in critically ill trauma patients.</p>\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":\"30 3\",\"pages\":\"158-163\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/JTN.0000000000000721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JTN.0000000000000721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:右美托咪定是一种α-2受体激动剂,常用于连续输注镇静镇痛;然而,剂量依赖性低血压可能限制其效用。尽管其广泛使用,但对适当的剂量和滴定尚无共识。目的:本研究的目的是确定右美托咪定剂量和滴定方案是否与创伤患者低血压发生率降低有关。方法:这项干预前研究于2021年8月至2022年3月在美国东南部的一家二级创伤中心进行,包括创伤服务部门在外科创伤重症监护病房或中级监护病房接受右美托咪定治疗超过或等于6小时的患者。如果患者在基线时处于低血压或使用血管加压药物,则排除。主要结局是低血压的发生率。次要结局包括给药和滴定方法、血管加压剂的起始、心动过缓的发生率和达到目标的时间里士满躁动镇静量表(RASS)评分。结果:59例患者符合纳入标准:干预前组30例,干预后组29例。术后组的方案依从性为34%,平均每位患者有一次违规。两组之间的低血压发生率相似(60%对45%,p = 0.243),但在零方案违规的组后患者中显著降低(60%对20%,p = 0.029)。注射后组的最大剂量也显著降低(1.1 vs 0.7 μg/kg/hr, p < 0.001)。在血管加压剂的开始、心动过缓的发生率或达到目标RASS的时间方面,两组无显著差异。结论:坚持右美托咪定给药和滴定方案可显著降低危重创伤患者低血压和最大右美托咪定剂量的发生率,且不增加达到目标RASS评分的时间。
Evaluating the Effect of a Dosing and Titration Protocol on Dexmedetomidine-Induced Hypotension in Trauma Patients.
Background: Dexmedetomidine is an α-2 receptor agonist commonly used as a continuous infusion for sedation and analgesia; however, dose-dependent hypotension may limit its utility. Despite its widespread use, there is no consensus on appropriate dosing and titration.
Objective: The objective of this study was to determine whether a dexmedetomidine dosing and titration protocol is associated with decreased rates of hypotension in trauma patients.
Methods: This pre-post intervention study took place at a Level II trauma center in the Southeastern United States from August 2021 to March 2022 and included patients admitted by the trauma service to either the surgical trauma intensive care unit or intermediate care unit and received dexmedetomidine for greater than or equal to 6 hours. Patients were excluded if they were hypotensive or on vasopressors at baseline. The primary outcome was incidence of hypotension. Secondary outcomes included dosing and titration practices, initiation of a vasopressor, incidence of bradycardia, and time to goal Richmond Agitation Sedation Scale (RASS) score.
Results: Fifty-nine patients met inclusion criteria: 30 in the pre-intervention group and 29 in the post-intervention group. Protocol adherence in the post group was 34% with a median of one violation per patient. Rates of hypotension were similar between the groups (60% vs. 45%, p = .243) but significantly lower in the post group patients with zero protocol violations (60% vs. 20%, p = .029). The post group also had a significantly lower maximal dose (1.1 vs. 0.7 μg/kg/hr, p < .001). There were no significant differences in the initiation of a vasopressor, incidence of bradycardia, or time to goal RASS.
Conclusion: Adherence to a dexmedetomidine dosing and titration protocol significantly decreased incidence of hypotension and maximal dexmedetomidine dose without increasing time to goal RASS score in critically ill trauma patients.